OUR PEOPLE: Innovation Board

The Innovation Board brings together the industrial and academic partners of the Consortium to determine the overarching challenges facing the pharmaceutical industry and predict future needs. It enables companies to collaborate on common research projects related to targets, technologies and therapeutic areas. The Consortium companies are in a position to fund collectively major projects of common interest. Its remit is to consider the future direction of therapeutic research and suggest innovative projects for collective company funding. Research projects selected by the Innovation Board are executed by a ‘task force’ of academic and company groups with appropriate expertise.

Dr John Lyons

Dr John Lyons

Astex
Senior Vice President of Translational Research

Dr Susan Galbraith

AstraZeneca
Vice President, Head of Oncology iMed, Innovative Medicines

Dr David Andrews

AstraZeneca
Associate Director Oncology Chemistry, Research & Development

Mark Morris

Dr Morten Persson

Ferring
Director, External Innovation Sourcing

Dr Rab Prinjha

Dr Rab Prinjha

GlaxoSmithKline
Vice President, Head of Epigenetics Drug Performance Unit (DPU)

Dr Richard Mason

Dr John Isaac

Johnson & Johnson
Senior Director, External Scientific Innovation, Neuroscience

Dr Richard Mason

Dr Lilian Alcaraz

Johnson & Johnson
Senior Director, New Ventures & Transactions, Neuroscience

Mark Morris

Dr Ann Connolly

Johnson & Johnson
Senior Director, New Ventures & Transactions, Infectious Disease and Vaccines

Mark Morris

Dr David Shields

Pfizer
Vice President and Head

Dr Kai Stoeber

Dr Kai Stoeber

Shionogi
Vice President,
Global Innovation

Prof Michael Wakelam

Prof Michael Wakelam

Babraham Institute
Director

Dr Simon Cook

Dr Simon Cook

Babraham Institute
Group Leader, Signalling Programme

Prof Greg Hannon

CRUK Cambridge Institute
Royal Society Research Professor

 

Dr Mathew Garnett

Dr Mathew Garnett

Sanger Institute
Group Leader, Translational Cancer Genomics

Ludovic Vallier

Prof Ludovic Vallier

University of Cambridge
Senior Group Leader, Laboratory for Regenerative Medicine
Prof Tony Kouzarides

Prof Tony Kouzarides

Milner Therapeutics Institute
Director

Dr Kathryn Chapman

Milner Therapeutics Institute
Deputy Director

Pin It on Pinterest